Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our team of dedicated scientists, clinicians and employees are focused on bringing new medicines to patients with debilitating diseases in cancer and immunology. Our research and development activities involves harnessing the immune system in the fight against cancer.
Key processes in the “Cancer immunity Cycle” must be activated, engaged, and promoted for an anticancer immune response to lead the effective killing of cancer cells.
Bempegaldesleukin (an investigational first-in-class CD122-preferential IL-2 pathway agonist), in combination with nivolumab (NIVO) a checkpoint inhibitor, leverages two immuno-oncology pathways with the aim of addressing the unmet needs of patients living with Kidney cancer.
KidneyCAN thanks Nektar Therapeutics for their generous contribution in support of #KCRS20 as a Community Partner.